Past News

VectivBio Announces Successful Opening of US IND for Apraglutide for Acute Graft-Versus-Host Disease

STARGAZE, a Phase 2, randomized, double-blind study, will assess the safety, tolerability, pharmacokinetic profile and efficacy of apraglutide in patients with steroid-refractory aGVHD. Dosing of the first patient is expected in 1Q 2022. Interim data read out is anticipated for 2H 2022.

UCB to License its AI Technology to ImageBiopsy Lab

Currently more than two-thirds of vertebral fractures are undiagnosed. Identifying them systematically has proven to be challenging for all clinicians. ImageBiopsy Lab will integrate UCB's BoneBot technology with its existing ImageBiopsy Lab ZOO MSK platform for delivery to hospitals to...

LumiraDx receives approval for its COVID-19 Antigen Test for use in India

Test combines sensitivity with speed and is designed to be used in health care settings to aid with rapid diagnosis of COVID-19

SpringWorks Therapeutics to Collaborate with Ab Magnitude on Target Identification and Discovery of Next-Generation Targeted Oncology Therapeutics

Collaboration Designed to Expand SpringWorks’ Drug Discovery Capabilities and to Support Buildout of Early-Stage Pipeline

Hardy Diagnostics Releases HardyCHROM™ Candida + auris

HardyCHROM™ Candida + auris can be used in conjunctions with Rapid Trehalose Broth or GlabrataQuick to aid in the identification of C. glabrata.  

NanoImaging Services Collaborates with Viva Biotech to Offer an Integrated CryoEM Gene-to-Structure Workflow to Streamline Target Discovery

This strategic partnership will bring together NanoImaging Services’ industry-leading expertise and innovation in high-resolution structural enablement by cryoEM and Viva Biotech’s world leading drug discovery platform to enable the management of projects from construct design through to final maps and subsequent protein supply.

Aegis Launches Infectious Disease Testing

Real-time PCR can detect low-level infections by amplification of specific genomic regions from a small amount of nucleic acid within a few hours.

Verifique™ Launches As the Fastest & Most Accurate At-home Drug Testing Kit on the Global Market

Verifique is the fastest and most accurate at-home drug testing kit on the global market, providing results in under 30 seconds.

Neoteryx’s Mitra Devices for Specimen Collection Registered in South Africa

"The SAHPRA registration confirms that Mitra® devices from Neoteryx meet all regulatory and quality standards in South Africa and can be imported for application in research and lab settings," said Nicolas Queisser, Managing Director, Separations.

Olive Diagnostics Reports Urine Analysis Enters Golden Era With World’s First Hands Free Optical Sensor For The Toilet Targeting Early Detection Of Disease In...

Dr. Joseph Rosenblum CMO eHealth Ventures said, "Olive's sophisticated technology, which delivers instant molecular detection of a moving urine stream, provides an innovative new direction and will make the current modes of spot testing via cumbersome cup-paper-dipstick obsolete."

Halo Labs Launches the Aura GT™ for Gene Therapy Product Quality

Aura GT can distinguish aggregated capsids from contaminants, carrier proteins, and other particles that might adversely harm patients.

Neurophth Announces the Completion of GMP Manufacturing Facility for Gene Therapy Products

"One of our key strategic priorities at Neurophth is to create gene therapies that can be manufactured consistently and rapidly while maintaining the international highest quality," said Alvin Luk, Chief Executive Officer of Neurophth.
spot_img

Latest News

Stealth BioTherapeutics Receives Refusal to File Letter from the FDA

Elamipretide was previously granted rare pediatric designation, fast track designation, and orphan drug designation by the FDA, and orphan drug designation by the European Medicines Agency (EMA), for the treatment of Barth syndrome. 

Opus Genetics Announces 2 Key Leadership Appointments

Opus Genetics, a patient-focused gene therapy company developing treatments for orphan inherited retinal diseases, today announced two key appointments...

VectivBio Announces Successful Opening of US IND for Apraglutide for Acute Graft-Versus-Host Disease

STARGAZE, a Phase 2, randomized, double-blind study, will assess the safety, tolerability, pharmacokinetic profile and efficacy of apraglutide in patients with steroid-refractory aGVHD. Dosing of the first patient is expected in 1Q 2022. Interim data read out is anticipated for 2H 2022.

Biotage Acquires ATDBio

The acquisition of ATDBio adds important platform solutions to Biotage within DNA and RNA oligonucleotide synthesis and purification.

Join Medical Device News Magazine's Mailing List: Receive a Weekly Recap of Device Industry News

spot_img